Chapters Transcript Video Using CBL0137 To Treat Patients With Advanced Extremity Melanoma or Sarcoma so a major question in all of oncology is how to offer efficacious treatments while minimizing toxicity. My name is Dr Joseph Skate Ski. I'm a surgeon and melanoma and sarcoma at Roswell Park Comprehensive Cancer Center, especially for sarcoma melanoma of the extremity. When they're advanced, we can often do regional therapy approach where we can isolate the circulation, give high doses of chemotherapy, and it can be curative. In certain situations. That treatment is relatively old. It was developed in the 19 fifties, and it uses a very toxic chemotherapy. The trial that I'm introducing involves CBL 1 37 and it's a novel agent that was developed here at Roswell Park by doctors Good Coffin Egorova, CBL 1 37. In preliminary study, it seems to be very efficacious. It actually seems to be as efficacious as standard chemotherapy but lacks the toxicity that we see with standard chemotherapies. The patients that have been treated on this clinical trial seemed to have done very well with minimal toxicity. Um, and it's too early to tell, but at least stable disease. So the idea behind using this drug for extremity melanoma, sarcoma is that when extremity tumors can be advanced. They're very difficult to treat, especially since some of them can be resistant to current treatments. The only option is amputation of those those extremities. This clinical trial was designed as a potentially limb salvaging procedure where amputation might be able to be avoided. Right now, we're in a clinical trial. That means we're still trying to figure out what the maximum dose is going to be and the most efficacious dose. Why this trial is important, and why this drug is important is that it changes the paradigm of regional therapies for cancer. It makes it much easier to deliver and potentially much less toxic. This clinical trial involves a 15 minute infusion. It's an intra arterial infusion of this novel agent, and it seems to be well tolerated and much less toxic than standard chemotherapy options. So the take home message is that this clinical trial is open. It's available wise will Park Comprehensive Cancer Center. It's available for patients that have melanoma, or sarcoma of the extremities that have failed all of the treatments. Uh, it can be potentially limb preserving and is unique and novel. Yeah, Created by
BROADCASTMED